|
Friday, September 22, 2017 |
|
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC |
Eisai Co., Ltd. announced today that the latest non-clinical data on MORAb-202, Eisai's first antibody-drug conjugate (ADC) developed by its research subsidiary Morphotek, Inc., was presented at the 8th Annual World ADC. more info >> |
|
Tuesday, September 19, 2017 |
|
エーザイ、「レンビマ(R)」(レンバチニブ)の全身化学療法歴のない切除不能な肝細胞がんを対象とした臨床第III相試験結果を第11回国際肝癌学会年次総会にて発表 |
エーザイ株式会社は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩(一般名、製品名:「レンビマ(R)」「Kisplyx(R)」、以下 レンバチニブ)に関する全身化学療法歴のない切除不能な肝細胞がんにおけるソラフェニブを対照薬とした臨床第III相試験(REFLECT/304 試験)について 1、B 型肝炎ウイルス由来の肝細胞がん患者様の部分集団解析結果を、韓国ソウルで開催された第 11 回国際肝癌学会年次総会にて初めて発表しましたのでお知らせします。 more info >> |
|
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference |
In the total population analysis of this study, the treatment effect of lenvatinib for all patients on the primary endpoint of Overall Survival (OS) was demonstrated by statistical confirmation of non-inferiority to sorafenib. more info >> |
|
Wednesday, September 13, 2017 |
|
エーザイ、ウイルス・菌を除去 抗菌作用が1週間続く持続型抗菌成分Etak(R)配合「イータック(R)抗菌化スプレーα 」新発売 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、ウイルス・菌を除去し、抗菌作用が1週間持続する、持続型抗菌成分Etak(R)配合の「イータック(R)抗菌化スプレーα(アルファ)」(雑貨)を9月19日(火)に新発売します。 more info >> |
|
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak |
Eisai Co., Ltd. will launch Etak Antimicrobial Spray Alpha (classified as miscellaneous goods), which contains long-acting antimicrobial agent Etak, on September 19. more info >> |
|
Tuesday, September 12, 2017 |
|
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out |
Eisai Co., Ltd. and MAMORIO, Inc. have announced that the MeMAMORIO tracking tool to support people with dementia and seniors going out will be launched in Japan on September 13. more info >> |
|
Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017 |
Eisai Co., Ltd. announced today that it has been selected for a fifth consecutive year of membership in the DJSI Asia Pacific, the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). more info >> |
|
Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress |
Eisai Co., Ltd. has announced that new findings indicating its in-house discovered and developed anticancer agent lenvatinib mesylate delays deterioration in certain areas of health-related quality of life (QOL) in comparison to sorafenib were presented in an oral session at the ESMO 2017 Congress, which took place in Madrid, Spain. more info >> |
|
Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima (Lenvatinib) in Combination with Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress |
Eisai Co., Ltd. announced today that an oral presentation on the results of the renal cell carcinoma cohort from a Phase Ib/II clinical study of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate. more info >> |
|
Friday, September 8, 2017 |
|
Conclusion of Development Collaboration Agreement for Lenvima (Lenvatinib Mesylate) and Opdivo (Nivolumab) Combination Therapy for Treatment of Hepatocellular Carcinoma |
Based on this agreement, Eisai and Ono will swiftly implement a Phase Ib clinical trial in Japan to investigate the safety, tolerability, and efficacy of the combination of Lenvima and Opdivo in patients with HCC. more info >> |
|
|
|